None
Quote | Kodiak Sciences Inc (NASDAQ:KOD)
Last: | $2.35 |
---|---|
Change Percent: | -1.36% |
Open: | $2.23 |
Close: | $2.35 |
High: | $2.39 |
Low: | $2.22 |
Volume: | 358,056 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Kodiak Sciences Inc (NASDAQ:KOD)
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Message Board Posts | Kodiak Sciences Inc (NASDAQ:KOD)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $KOD 23% v1,6M c6.04 f52,309M H6.11 ML4.62=LL | znewcar1 | investorshangout | 03/30/2023 3:27:07 AM |
Can eyes revived after death open the door | maverick_1 | investorshub | 03/28/2023 11:53:23 AM |
znewcar1: KOD 23% v4,1M c10.05 f51,95M H10.25 ML6.6 strong vol day | znewcar1 | investorshangout | 07/07/2022 9:26:34 PM |
Regardless of what happened in feb this still | JPro | investorshub | 03/22/2022 5:52:11 PM |
responding from a post from 2019? interesting... | ClayTrader | investorshub | 02/25/2022 12:24:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...